27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
Zentalis Pharmaceuticals Inc (NASDAQ:ZNTL) announced initial efficacy and safety data from the ongoing Phase 1b trial of ZN-c3 combined with chemotherapy in patients with platinum-resistant or -refractory ovarian cancer.
- Data were reviewed at the American Association of Cancer Research (AACR) Annual Meeting.
- The study consists of four cohorts: ZN-c3 + PLD, ZN-c3 + carboplatin, ZN-c3 + paclitaxel, and ZN-c3 + gemcitabine.
- ZN-c3, in combination with chemotherapy, demonstrated anti-tumor activity in a heavily pretreated population, with an objective response rate (ORR) of 30.2% across all evaluable chemotherapy cohorts.
- ZN-c3 + paclitaxel cohort achieved an ORR of 62.5%.
- ZN-c3 was generally well-tolerated in combination with chemotherapy and exhibited lower hematologic toxicity and a better gastrointestinal tolerability profile than the Wee1 inhibitor class.
- The most common treatment-related adverse events at all grades included nausea (48.2%), neutropenia (41.1%), thrombocytopenia (37.5%), vomiting (30.4%), and anemia (26.8%).
- Price Action: On Friday, ZNTL shares gained 4.95% to $35.65 in after-hours trading.
27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!